Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline

Monica Crugnola, Fausto Castagnetti, Massimo Breccia, Dario Ferrero, Malgorzata Monika Trawinska, Elisabetta Abruzzese, Mario Annunziata, Fabio Stagno, Mario Tiribelli, Gianni Binotto, Massimiliano Bonifacio, Carmen Fava, Alessandra Iurlo, Cristina Bucelli, Giovanna Mansueto, Antonella Gozzini, Franca Falzetti, Enrico Montefusco, Elena Crisà, Gabriele GugliottaSabina Russo, Michele Cedrone, Antonella Russorossi, Patrizia Pregno, Alessandro Isidori, Endri Mauro, Romano Atelda, Gianfranco Giglio, Francesca Celesti, Federica Sora', Sergio Storti, Adam D’Addosio, Sara Galimberti, Ester Orlandi, Elisabetta Calistri, Monica Bocchia, Francesco Cavazzini, Giovanna Rege Cambrin, Nicola Orofino, Luigiana Luciano, Nicola Sgherza, Gianantonio Rosti, Roberto Latagliata, Isabella Capodanno

Risultato della ricerca: Contributo in rivistaArticolo in rivistapeer review

6 Citazioni (Scopus)


PURPOSE: We performed a nationwide registry-based analysis to describe the clinical outcome of adults patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) who underwent an allogeneic hematopoietic stem cell transplantation (HSCT) after a TKI-based treatment. PATIENTS AND RESULTS: A total of 441 patients were included in the study. The median age at HSCT was 44 years (range 18-70). All the 441 patients (100%) received TKI before the HSCT (performed between 2005 and 2016). Of these patients, 404 (92%) were in cytologic complete remission (CR), while the remaining 37 (8%) had an active disease at the time of HSCT. Molecular minimal residual disease (MRD) was negative in 147 patients (36%) at the time of HSCT. The donor was unrelated in 46% of cases. The prevalent source of stem cells was peripheral blood (70%). The conditioning regimen was myeloablative in 82% of cases (TBI-based in 50%) and included ATG in 51% of cases. With a median follow-up after HSCT of 39.4 months (range: 1-145), the overall survival (OS) probability at 1, 2 and 5 years was 69.6%, 61.1% and 50.3%, respectively, with a median OS of 62 months. Progression-free survival (PFS) at 1, 2 and 5 years was 60.2%, 52.1% and 43.7%, respectively. OS and PFS were significantly better in patients with CR and MRD-negative at the time of transplant compared with those of patients with CR but MRD-positive (50% OS not reached vs. 36 months, P=0.015; 50% PFS not reached vs. 26 months, P=0.003). The subgroup of MRD-negative patients both at HSCT and at 3 months after HSCT had a better outcome (5 years OS rate 70%). Conversely, the 37 patients who underwent a HSCT with active Ph+ ALL had a median OS and PFS of 7 and 5 months, respectively. The 5 years cumulative incidence of relapse was significantly lower in MRD-negative patients (19.5% vs. 35.4%, P=0.001). The non-relapse mortality (NRM) after 1, 2 and 5 years was 19.1% (95%CI: 15.5-22.9), 20.7% (95%CI: 17-24.7) and 24.1% (95%CI: 20-28.5), respectively. The NRM was significantly lower with a mEBMT risk score of 0-2 compared with mEBMT risk score of ≥ 3 (15% vs. 25%, P=0,016). CONCLUSIONS: The median OS for Ph+ ALL patients who underwent a TKI-based treatment followed by an allograft, in recent years at the GITMO Centers, was 62 months. Evaluation of the mEBMT risk score can be useful to predict NRM. Our data confirm that HSCT is a potentially curative treatment for Ph+ ALL with an excellent outcome for the subgroup of patients MRD-negative both at HSCT and at 3 months after HSCT (5 year OS 70%).
Lingua originaleEnglish
pagine (da-a)2329-2338
RivistaAnnals of Hematology
Stato di pubblicazionePubblicato - 2019


  • Chronic myeloid leukaemia
  • Elderly
  • Outcome
  • Tyrosine kinase inhibitor


Entra nei temi di ricerca di 'Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline'. Insieme formano una fingerprint unica.

Cita questo